{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-26-000011","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2026-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.398306+00:00","generated_at":"2026-05-15T12:39:09.591358+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026","bullets":["Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.","Cash, cash equivalents & restricted cash $71.9M at Dec 31, 2025, down from $112.4M YoY.","Net loss of $66.5M ($1.64 per share) in 2025 vs $61.1M ($1.55) in 2024.","R&D expenses decreased to $25.6M from $42.2M due to deprioritization of legacy assets.","VTP-1000 multiple ascending dose data in celiac expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-26-000011","json":"https://secwatch.observer/filing/0001828185-26-000011.json","markdown":"https://secwatch.observer/filing/0001828185-26-000011.md","text":"https://secwatch.observer/filing/0001828185-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818526000011/0001828185-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818526000011/brns-20260313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:39:09.591358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}